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Parathyroid hormone (PTH) and vitamin D have been recognized as the main regulators of phosphate homeostasis. 1 PTH accomplishes it via two opposite eff ects: it reduces serum phosphate by decreasing its renal reabsorption, and increases it either by directly stimulating bone turnover and phosphate release or by indirectly stimulating intestinal phosphate absorption through its stimulatory effect on renal 1 -hydroxylase activity and 1,25(OH) 2 D 3 (calcitriol) production. PTH binds to PTH / PTHrP receptor type 1 (PTHR1) in renal and bone cells and activates several intracellular second messengers, including Gsdependent cyclic adenosine monophosphate (cAMP), inositol triphosphate, phospholipase C, free calcium, and diacylglycerol. 1 Some of them, namely, cAMP and phospholipase C, lead to the internalization of the sodium -phosphate cotransporters NPT2a and NPT2c in proxi mal tubular cells, and to a fall in renal phosphate reabsorption. In bone cells, PTHR1s are found mostly in osteoblasts, and not in osteoclasts, which confers to PTH its anabolic action, increasing bone formation. However, most importantly physiologically, PTH stimulates osteoblast RANKL (receptor activator of nuclear factor-B ligand) production, which in turn increases osteoclast number, bone resorption, and subsequently phosphate release. 1 Active vitamin D, or calcitriol, results from a cascade of metabolic steps beginning with cutaneous ultraviolet-dependent generation of cholecalci ferol from 7-dehydrocholesterol and ergosterol, followed by liver 25-hydroxylation of cholecalciferol, and lastly by renal 1 - 3 Klotho is expressed mainly in distal tubular cells, which contrasted, at the beginning, with the phosphaturic eff ect of FGF23 in proximal tubules; however, klotho expression is also present in proximal tubular cells. Klotho can also be shed from the cellular membrane by metalloproteases, and released into the circulation in a soluble form of smaller molecular weight with not yet fully understood physio logical functions. 4 FGF23 and klotho may regulate PTH, as evidenced by the expression of all players involved in FGF23 signaling in parathyroid glands, including FGFR1, FGFR3, and klotho. FGF23 directly decreases PTH mRNA expression and PTH secretion in vitro as well as in in vivo experiments. It may also indirectly repress the PTH gene through the stimulation of parathyroid 1 -hydroxylase activity and local production 5 as well as in one case of hyperphosphatemic familial tumoral calcinosis due to an inactivating klotho mutation. 6 Inversely, and independently of FGF23, klotho stimulates PTH secretion through the stabilization of Na / K-ATPase at the cell membrane. 7 However, to date, it is unknown whether klotho, FGF23, and FGFR1 interact with the CaR, the main regulator of PTH secretion.
Overexpression of FGF23 and injection of FGF23 into mice cause hypophosphatemia and reduce calcitriol; inversely, mice lacking FGF23 have hyperphosphatemia and high calcitriol. Similarly, the phenotype of klotho-deficient mice is quite similar to that of FGF23 knockout animals, depicting hyperphosphatemia, high calcitriol, and reduced lifespan, suggesting that these abnormalities occur because FGF23 cannot act on the organs where klotho is normally expressed, namely, the kidney and para thyroid gland. 3 Intriguingly, most of the phenotype of FGF23 and klotho knockout mice can be rescued by a phosphate-restricted diet, and by disruption of vitamin D signaling pathways by the silencing of either the VDR or the 25-hydroxyvitamin D-1 -hydroxylase gene. Th ese fi ndings demonstrate that the presence or the absence of klotho determines the tissue specifi city and the eff ects of FGF23.
L ó pez et al. 8 (this issue) asked whether PTH could regulate skeletal FGF23 production. Th ey hypothesized that if FGF23 reduces PTH, this should lead to hypocalcemia and hyperphosphatemia. Such hypocalcemia would be magnifi ed by low calcitriol and hyperphosphatemia. Th erefore, there should be a mechanism protecting against the hypocalcemia in case of persistent high FGF23, and this mechanism should block FGF23 production. The decreased synthesis of calcitriol induced by low PTH actually inhibits FGF23 production, but, on the other hand, the increase in phosphate that follows low PTH levels would tend to stimulate FGF23 synthesis. PTH might be necessary for FGF23 secretion, and thus low PTH would result in decreased FGF23. Th is would also help to understand the contradictory action of FGF23 on plasma phosphorus. FGF23 directly decreases plasma phosphate, while, indirectly through decreasing PTH, it facilitates an increase of serum phosphate.
Th e authors found paradoxically low FGF23 levels in parathyroidectomized (PTX) animals in spite of hyperphosphatemia, suggesting that phosphate alone was unable to stimulate FGF23 synthesis, and that other factors such as PTH and / or calcitriol were required. Th is assumption should be taken with caution, since, despite low PTH and calcitriol, high FGF23 is seen in PTH-null mice and in patients with hypoparathyroidism. Similarly, aft er total parathyroidectomy, the peak of serum phosphate always precedes FGF23 increase by several days, illustrating that phosphate is the primary stimulus for FGF23 production. Low PTH was probably not solely responsible for the low FGF23 in PTX animals. As the authors discuss, calcitriol was also decreased, which is probably more important than stimulation of FGF23 by PTH. Indeed, vitamin D regulates FGF23 independently of phosphate, as suggested by the reduced FGF23 levels in animals with VDR gene knockout selectively in chondrocyte cells. However, it remains to be investigated what would be the eff ect of supraphysiological doses of PTH on serum FGF23 levels in vitamin D-deprived animals, either by VDR or CYP27B1 knockout or by binephrectomy. It is also unknown how parathyroidectomy would modify the number and activity of bone cells producing FGF23.
Th e administration of physiological and supraphysiological doses of PTH in The only source of phosphate is external, from daily dietary food, which has to travel in the gut and become available for intestinal absorption, either actively through the cells or passively through the paracellular pathway. Once absorbed, inorganic phosphate enters into the extracellular compartment, particularly into the circulating plasma, where its concentration is tightly regulated by the three organs depicted here, parathyroid, bone, and kidney, interacting with one another through three feedback loops. Parathyroid glands produce parathyroid hormone (PTH), which, on the kidney, stimulates phosphate excretion and calcitriol synthesis; then, in turn, low phosphate and calcitriol directly inhibit PTH production. On the bone, PTH stimulates fibroblast growth factor 23 (FGF23) production and phosphate release following an increase in bone remodeling. FGF23 inhibits PTH secretion, but phosphate will tend to stimulate PTH production. FGF23, at the kidney level, stimulates urinary phosphate excretion and inhibits calcitriol production, tending to reduce serum phosphate levels by these two mechanisms. On the other hand, the renal PTH-stimulated calcitriol production stimulates FGF23 production by bone cells. These three counterregulatory loops maintain tightly controlled intestinal absorption and serum phosphate concentration. Certainly, there is now evidence that there should be an intestinal phosphate sensor that alerts one of these organs (the kidney), or probably more than one (dashed lines), in case of phosphate overload or phosphate deficiency.
PTX animals increased FGF23 and calcitriol and normalized serum phosphate levels. Several observations had already suggested that PTH could stimulate skeletal FGF23 production. Administration of (1-34)PTH to healthy individuals increased serum FGF23. Moreover, constitutively activated PTHR1 in Jansen ' s disease, which can be considered as a primary hyperparathyroidism with high PTH and hypophosphatemia, showed elevated FGF23. 9 Similarly, high FGF23 is oft en seen in secondary hyperparathyroidism and can predict its severity and its resistance to vitamin D therapy in chronic kidney disease patients. 10 In the same patients, serum FGF23 signifi cantly declined aft er parathyroidectomy. L ó pez et al. 8 confi rm and extend these previous fi ndings, demonstrating that PTH, either directly or indirectly via calcitriol, is necessary for skeletal FGF23 production.
Probably, one of the most interesting fi ndings of this study is the lack of eff ect of FGF23 on urinary and serum phosphate in the absence of PTH. PTX animals receiving physiological doses of calcitriol had high FGF23 but did not normalize serum phosphate, implying that, at least in the kidney, there was a key factor regulated by PTH that was required for the phosphaturic action of FGF23. Th is factor was certainly klotho, as the authors found a reduction of klotho expression in the kidneys of PTX animals. Importantly, renal klotho expression was restored to normal levels aft er PTH supplementation, allowing FGF23 to exert its phosphaturic action and the normalization of serum phosphate levels.
In summary, the study by L ó pez et al. 8 shows that PTH is necessary in maintaining normal circulating FGF23 levels, that changes in calcitriol levels unquestionably play a role in the stimulatory eff ect of PTH on FGF23, and that PTH regulates klotho expression in the kidney and thereby the phosphaturic eff ect of FGF23. It confi rms the existence of three feedback loops, involving parathyroid glands, bone, and kidney, regulating serum phosphate concentration ( Figure  1 ) and opens a number of areas for clinical and experimental research in the fi eld of phosphate homeostasis.
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Since 1883, when Ringer discovered that a trace amount of Ca 2 + from tap water was suffi cient to induce contraction of a frog ' s heart, the role of Ca 2 + in regulating physiological functions has been continually investigated. We now know that appropriate concentrations of extracellular and intracellular Ca 2 + are vital to the survival of all organisms from the simplest unicellular organism to mammals and that highly regulated processes are required to provide constant and appropriate quantities of the ion to cells and tissues. Therefore, sophisticated mechanisms enable cells to detect minor changes in extracellular Ca 2 + content to counteract and modify their behavior accordingly.
In major organisms, Ca 2 + has to be controlled both systemically and locally, and in mammals, the control of systemic calcium homeostasis is mediated by the calcium-sensing receptor (CaSR).
see original article on page 483
Calcium sensing in podocytes Besides its primary function in maintaining systemic calcium homeostasis, the calcium-sensing receptor (CaSR) is expressed by many cell types, with different, sometimes opposite, regulatory functions. Novel work from Oh and collaborators shows that activation of CaSR in podocytes has prosurvival effects and protects the cell from puromycin aminonucleoside damage. Given that the cellular consequences of CaSR activation are largely context-dependent, further studies will be required to elucidate its precise role in podocyte physiology and pathophysiology.
